• Mashup Score: 5

    Circulating tumor DNA (ctDNA) is a promising non-invasive tool that has been demonstrated to be a clinically useful biomarker in several tumor types for risk stratification, prognosis, and early detection of recurrence. However, there are limited data on the clinical utility of ctDNA in endometrial cancer (EC) compared with other solid tumors. The evolution of EC management through the integration of molecular characterization into the treatment algorithm has intensified the need to develop more effective predictive biomarkers to optimize treatment and reduce clinical toxicities.

    Tweet Tweets with this article
    • RT @IJGConline: ctDNA in #endometrialcancer: clinical significance and implications @IlariaCapasso12 🧬 https://t.co/Yz3gkjzZZI @pedrorami…